Journal
VACCINE
Volume 27, Issue 48, Pages 6695-6703Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.08.091
Keywords
Leishmania infantum; Canine visceral leishmaniasis; LACK; Antibiotic resistance free DNA vaccine; Modified vaccinia virus Ankara
Categories
Funding
- Spanish Ministry of Science and Innovation [AGL 2007-66308-C02-01/GAN, FPI/BES-2004-4847]
- CSIC [JAE-Doc027, I3P-BPD2003-1]
- Animal Health Spain Co
Ask authors/readers for more resources
Canine visceral leishmaniasis is a serious public health concern in the Mediterranean basin since dogs are the main Leishmania infantum reservoir. However, there is not a vaccination method in veterinary use in this area, and therefore the development of a vaccine against this parasite is essential for the possible control of the disease. Previous reports have shown the efficacy of heterologous prime-boost vaccination with the pCIneo plasmid and the poxvirus VV (both Western Reserve and MVA strains) expressing L. infantum LACK antigen against canine leishmaniasis. As pCIneo-LACK plasmid contains antibiotic resistance genes, its use as a profilactic method is not recommended. Hence, the antibiotic resistance gene free pORT-LACK plasmid is a more suitable tool for its use as a vaccine. Here we report the protective and immunostimulatory effect of the prime-boost pORT-LACK/MVA-LACK vaccination tested in a canine experimental model. Vaccination induced a reduction in clinical signs and in parasite burden in the liver, an induction of the Leishmania-specific T cell activation, as well as an increase of the expression of Th1 type cytokines in PBMC and target organs. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available